Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immune Design CS (IMDZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 246,750
  • Shares Outstanding, K 25,570
  • Annual Sales, $ 13,260 K
  • Annual Income, $ -53,530 K
  • 36-Month Beta 2.74
  • Price/Sales 16.30
  • Price/Cash Flow 0.00
  • Price/Book 2.54

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.47 +49.15%
on 06/05/17
9.89 -2.43%
on 06/22/17
+2.25 (+30.41%)
since 05/23/17
3-Month
5.45 +77.06%
on 05/08/17
9.89 -2.43%
on 06/22/17
+3.15 (+48.46%)
since 03/23/17
52-Week
4.50 +114.44%
on 11/03/16
9.89 -2.43%
on 06/22/17
+1.35 (+16.27%)
since 06/23/16

Most Recent Stories

More News
No Energy to Follow Through

No Energy to Follow Through

HIVE : 5.42 (+3.24%)
RWLK : 2.40 (+33.33%)
COP : 44.83 (+0.04%)
IMDZ : 9.65 (+14.20%)
VRTX : 133.50 (-1.50%)
EPZM : 14.70 (+7.69%)
Immune Design (IMDZ) Up 22.6% Since Earnings Report: Can It Continue?

Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMDZ : 9.65 (+14.20%)
Immune Design Updates Positive Data from Lead Cancer Immunotherapy Programs at ASCO Annual Meeting

-- Observed median overall survival for sarcoma patients treated in two separate Phase 1 studies with an NY-ESO-1 targeted novel immunotherapy meaningfully exceeds standard of care benchmarks

IMDZ : 9.65 (+14.20%)
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1

Immune Design Corp. (IMDZ) reported first-quarter 2017 loss of 50 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents and also a year-ago loss of 61 cents.

MRK : 66.16 (+0.21%)
IMDZ : 9.65 (+14.20%)
RHHBY : 32.7600 (+1.42%)
SNY : 49.33 (-0.56%)
New Clinical and Biomarker Data Validate Immune Design's Lead Programs and Discovery Platforms

Data from CMB305 and G100 to be Presented at ASCO Annual Meeting in June 2017

IMDZ : 9.65 (+14.20%)
4 Drug Stocks Poised to Beat this Earnings Season

M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.

ENDP : 11.84 (+1.63%)
JNJ : 136.43 (+0.28%)
IMDZ : 9.65 (+14.20%)
LLY : 83.89 (-0.50%)
IONS : 54.97 (+0.46%)
EDIT : 17.95 (+2.34%)
GILD : 70.52 (+0.06%)
BIIB : 280.32 (-0.09%)
What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?

Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.

IMDZ : 9.65 (+14.20%)
IONS : 54.97 (+0.46%)
EDIT : 17.95 (+2.34%)
RHHBY : 32.7600 (+1.42%)
Immune Design to Report First Quarter 2017 Financial Results & Provide Corporate Update

Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report first quarter 2017 financial results and provide a corporate update after the...

IMDZ : 9.65 (+14.20%)
Mylan (MYL) Q1 Earnings: Will the Stock Pull a Surprise?

Mylan N.V. (MYL) is scheduled to report first-quarter 2017 results on May 10, before the market opens.

MYL : 39.03 (+0.05%)
HZNP : 11.73 (-1.18%)
IMDZ : 9.65 (+14.20%)
FGEN : 32.25 (-0.31%)
What's in the Cards for Repros (RPRX) this Earnings Season?

Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.

RPRX : 0.39 (-4.88%)
AUPH : 6.63 (+3.76%)
IMDZ : 9.65 (+14.20%)
FGEN : 32.25 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305,...

See More

Support & Resistance

2nd Resistance Point 10.68
1st Resistance Point 10.16
Last Price 9.65
1st Support Level 8.67
2nd Support Level 7.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.